• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • SOD1 Therapies & Trials
      • SPG302
      • T Regulatory Cell Therapies
      • Ulefnersen – Ionis Pharmaceuticals
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

SEED Grant Program

The SEED Grant Program: Supporting Excellence, Equity, and Discovery for ALS/MND

ALS/MND affects people in every part of the world. Yet many regions remain significantly under-represented in ALS/MND research — not because the need is less, but because the foundational infrastructure for research participation is still developing.

The SEED (Supporting Excellence, Equity, and Discovery for ALS/MND) Grant Program was created to help change that.

This program is made possible through founding support from FightMND and ALS Canada, with growing support from across the global ALS/MND community.

About SEED

SEED provides early-stage funding to support efforts that strengthen ALS/MND research infrastructure and readiness in low-income, lower-middle-income, and upper-middle-income countries, based on World Bank country income classifications or countries designated as Developing Economies (Global South) according to the UN classification. 

Eligible projects focus on practical steps that create, connect, or strengthen the people, systems, partnerships, data pathways, and infrastructure needed for ALS/MND research. These efforts may help local or regional teams prepare for work in one or more areas, including ALS/MND registries, biobanking preparation, data collection pathways, genetic and epidemiological studies, clinical trial readiness, or locally relevant pilot work.

Projects may include ALS/MND–FTD overlap if the FTD-related component is directly connected to ALS/MND research readiness. Projects focused only on FTD are outside the scope of this program.

The goal is to support local leaders, institutions, and networks as they build the foundations needed for future ALS/MND research, collaboration, and larger-scale funding.

Key Dates

  • Applications open: June 21, 2026
  • Application deadline: September 1, 2026
  • Recipients notified: Late October/early November 2026
  • Public announcement: December 5–6, 2026, at the International Alliance Meeting in Amsterdam

Who Can Apply

SEED is open to:

  • Researchers
  • Clinicians
  • Academic institutions
  • Hospitals and clinics
  • Research networks
  • Multi-site collaborations
  • Regional partnerships

Applications may be submitted by individual organizations or collaborative groups.

Collaborations with high-income countries are welcome when they strengthen research readiness, leadership, ownership, and benefit within an eligible country.

SEED welcomes applications from teams at different stages of ALS/MND research readiness, including those building early research capacity and those strengthening emerging networks or infrastructure.

How to Apply

Applications for the 2026 SEED Grant Program opened on June 21, 2026. The deadline to apply is September 1, 2026.

Apply Now

Before starting an application, please review the full application materials:

  • SEED Request for Proposals (PDF)
  • SEED Frequently Asked Questions (PDF)
  • SEED Budget Template (Excel)
  • SEED CV/Biosketch Template (Word document)
  • SEED Institutional Letter of Support Template (Word document)

How Applications Will Be Reviewed

Applications will be reviewed, scored, and ranked by an International Peer Review Panel with expertise in ALS/MND and/or related neurological diseases, and familiarity with ALS/MND research needs in eligible countries.

Applications will be assessed for significance and impact, project rationale and design, team capability, project feasibility, capacity-building value, and fit with the SEED program purpose. The panel will make funding recommendations based on the quality of applications and the pool of available funds.

SEED recognizes that applicants will come from regions with different levels of existing ALS/MND research infrastructure. Reviewers will consider the local starting point, the need being addressed, and whether the proposed work can create measurable progress toward ALS/MND research readiness in that region.

Funding Available

Applicants may request up to US$50,000. The total number of awards will depend on available funding and the size of the selected proposals.

The maximum award amount is inclusive of all costs, including direct costs, indirect costs, institutional overheads, and any applicable taxes or fees. Indirect costs, including institutional overheads, may not exceed 5% of the total budget requested.

Applicants do not need to request the maximum amount. Smaller, focused proposals may be appropriate if the project has a clear purpose, a realistic plan, and a measurable outcome.

Questions

Please review the application materials and FAQ before reaching out.

For questions about eligibility, project fit, application requirements, or budget preparation, contact seed@als-mnd.org.

Primary Sidebar

  • Juvenal Bayona Romero, Colombia

    Juvenal Bayona Romero, Colombia

  • Phil Rossall, UK

    Phil Rossall, UK

  • John Sweeney, USA

    John Sweeney, USA

  • PALS and CALS, Singapore

    PALS and CALS, Singapore

  • Brigitte Wernli, Switzerland

    Brigitte Wernli, Switzerland

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Carlos Alberto Arango, Colombia

    Carlos Alberto Arango, Colombia

  • Colm Francis Davis, Ireland

    Colm Francis Davis, Ireland

  • Den Haag, Netherlands

    Den Haag, Netherlands

  • Mike Cels, Canada

    Mike Cels, Canada

  • David Hall, USA

    David Hall, USA

  • Roxana Canova, Argentina

    Roxana Canova, Argentina

  • Frank Bos, Netherlands

    Frank Bos, Netherlands

  • Fabio Correia, Brazil

    Fabio Correia, Brazil

  • Eddy Lefrancois, Canada

    Eddy Lefrancois, Canada

  • Sharon Corosanite, USA

    Sharon Corosanite, USA

  • Ann Nicol, USA

    Ann Nicol, USA

  • Rudiger Hanemann, Germany

    Rudiger Hanemann, Germany

  • Sanjay Kumar Srivastava, India

    Sanjay Kumar Srivastava, India

  • Jay Epstein, USA

    Jay Epstein, USA

  • Angela Jansen, Germany

    Angela Jansen, Germany

  • Bjarne Hytjanstorp, Norway

    Bjarne Hytjanstorp, Norway

  • Ismail Gokcek, Turkey

    Ismail Gokcek, Turkey
    ismail_gokcek_alsmnd_tr

  • Lin Yong Yi, Taiwan

    Lin Yong Yi, Taiwan

  • Karl Hughes, Ireland

    Karl Hughes, Ireland

  • Norm MacIsaac, Canada

    Norm MacIsaac, Canada

  • Susan Keldani, USA

    Susan Keldani, USA

  • Amparo Muriel Engativa, Colombia

    Amparo Muriel Engativa, Colombia

  • Torben Mikkelsen, Denmark

    Torben Mikkelsen, Denmark

  • Mark Miller, UK

    Mark Miller, UK

  • Graham Johnson, Australia

    Graham Johnson, Australia

  • Margreth Burger-Saile, Switzerland

    Margreth Burger-Saile, Switzerland

  • Daniela Maria Daverio, Argentina

    Daniela Maria Daverio, Argentina

  • Angelique van der Lit-van Veldhuizen, Netherlands

    Angelique van der Lit-van Veldhuizen, Netherlands

  • Shera Mukherjee, India

    Shera Mukherjee, India

  • Erwin Coppejans, Belgium

    Erwin Coppejans, Belgium

  • Bayley, Australia

    Bayley, Australia

  • Cliff Marshman, USA

    Cliff Marshman, USA
    CliffMarshman

  • Aida Trzmiel de Guterman, Argentina

    Aida Trzmiel de Guterman, Argentina

  • Jason Goodman, USA

    Jason Goodman, USA

  • Yannick Richard, Canada

    Yannick Richard, Canada
    yannickrichard

  • Andres Estevez Guersznik, Ireland

    Andres Estevez Guersznik, Ireland

  • Sally Pauls, USA

    Sally Pauls, USA

  • Bob Simonds, USA

    Bob Simonds, USA

  • Rolf Mauch, Switzerland

    Rolf Mauch, Switzerland

  • Ali Var, Turkey

    Ali Var, Turkey

  • Willi Klein, UK

    Willi Klein, UK

  • Hiroshi Matsuyama, Japan

    Hiroshi Matsuyama, Japan

  • Fayette Underwood, USA

    Fayette Underwood, USA

  • Eric Von Schaumburg, USA

    Eric Von Schaumburg, USA

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login